Stuart Therapeutics Unveils Breakthrough Phase 3 Clinical Trial for Vezocolmitide

Stuart Therapeutics Unveils Breakthrough Phase 3 Clinical Trial for Vezocolmitide, a Potential Game-Changer in Dry Eye Disease Treatment

Stuart Therapeutics, Inc. (“Stuart”), a cutting-edge biopharmaceutical company specializing in extracellular matrix-targeting peptide therapeutics for ophthalmic diseases, has marked a…